Drugs & Targets FDA grants accelerated approval to Lunsumio for R/R follicular lymphoma January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves first gene therapy for high-risk, non-muscle-invasive bladder cancer January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves imaging drug to help identify lung cancer lesions January 06, 2023Vol.49 No.01
Drugs & Targets FDA accepts supplemental BLAs for Padcev + Keytruda for urothelial cancer January 06, 2023Vol.49 No.01
Drugs & Targets Panel submits operational evaluation of FDA’s tobacco program January 06, 2023Vol.49 No.01
Drugs & Targets EC approves allogeneic T-cell immunotherapy in rare cancer January 06, 2023Vol.49 No.01
Drugs & Targets Caris and Xencor expand collaboration for XmAb antibody drug candidates January 06, 2023Vol.49 No.01
Drugs & Targets C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D January 06, 2023Vol.49 No.01
Drugs & Targets Gilead to acquire remaining rights to immunotherapy GS-1811 from Jounce January 06, 2023Vol.49 No.01
